2024
Perceptions of delayed alopecia among breast cancer survivors
Premji S, Ruddy K, Vierkant R, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch F, Olson J, Cathcart-Rake E. Perceptions of delayed alopecia among breast cancer survivors. Clinical Breast Cancer 2024 DOI: 10.1016/j.clbc.2024.09.008.Peer-Reviewed Original ResearchBreast cancer survivorsMayo Clinic Breast Disease RegistryCancer survivorsChemotherapy recipientsStage I-III breast cancerI-III breast cancerBreast cancer diagnosisPersistent bothersome symptomsRespondents' median ageBreast cancer treatmentMental healthDistressing symptomsDisease RegistryCancer diagnosisCohort studyHair lossSurvivorsBreast cancerBothersome symptomsBreastRespondentsSurvey 6 yearsParticipantsBotherCancer treatment
2023
Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity
Haynam M, Chaplow Z, DeScenza V, Bowman J, Dispennette K, Zhang X, Kilar M, Hohn S, Fairman C, Lustberg M, Focht B. Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity. Contemporary Clinical Trials Communications 2023, 33: 101154. PMID: 37250507, PMCID: PMC10220259, DOI: 10.1016/j.conctc.2023.101154.Peer-Reviewed Original ResearchBreast cancer survivorsLifestyle weight management interventionsWeight management programWeight management interventionsPilot trialCancer survivorsPreliminary efficacyPilot intervention trialPatient-reported outcomesLifestyle behavior changeSignificant weight gainBreast cancer treatmentMode of deliveryCommunity-based intervention modelMulti-component interventionCommunity-based interventionsQuality of lifeTrial feasibilityDietary modificationCardiometabolic diseasesIntervention trialsCancer recurrenceEfficacy trialsOverweightWeight gain
2022
The Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients
Bennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients. Current Developments In Nutrition 2022, 6: 6009237. PMCID: PMC9193887, DOI: 10.1093/cdn/nzac052.004.Peer-Reviewed Original ResearchPlasma concentrationsCognitive impairmentLong-term cognitive impairmentNutritional targetsDocosahexaenoic acidNervonic acidEicosapentaenoic acidOmega-3 fatty acidsNeo-adjuvant chemotherapyBreast cancer patientsEffect of chemotherapyBreast cancer chemotherapyFatty acidsBreast cancer treatmentHippocampal concentrationsDietary interventionSolid tumor treatmentCancer patientsChemotherapy treatmentFatty acid concentrationsObjective biomarkersBreast cancerImpact of visitsChemotherapyMead acid
2016
Effects of exercise interventions during different treatments in breast cancer.
Fairman C, Focht B, Lucas A, Lustberg M. Effects of exercise interventions during different treatments in breast cancer. The Journal Of Community And Supportive Oncology 2016, 14: 200-9. PMID: 27258052, PMCID: PMC5522734, DOI: 10.12788/jcso.0225.Peer-Reviewed Original ResearchExercise interventionD effect sizesTreatment-related adverse effectsFemale breast cancer survivorsPsychosocial outcomesEfficacy of exerciseBreast cancer survivorsBreast cancer patientsBreast cancer treatmentActive cancer therapyPost-treatment interventionsType of treatmentCohen's d effect sizesCancer survivorsResistance exerciseAerobic exerciseCancer patientsInclusion criteriaMuscular strengthCardiovascular functioningLiterature searchCancer treatmentAdverse effectsModerate improvementCancer therapy
2015
Impact of breast cancer treatment on body mass index (BMI) over time.
Reinbolt R, Pan X, Wandell K, Pilarski R, Layman R, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg M. Impact of breast cancer treatment on body mass index (BMI) over time. Journal Of Clinical Oncology 2015, 33: 94-94. DOI: 10.1200/jco.2015.33.28_suppl.94.Peer-Reviewed Original ResearchBody mass indexBreast cancer patientsEndocrine therapyAromatase inhibitorsWeight gainBMI changeCancer patientsEarly placebo-controlled trialsInitial body mass indexEarly-stage breast cancerHigher body mass indexBody mass index (BMI) changeBreast cancer patient cohortsPlacebo-controlled trialRetrospective chart reviewStage breast cancerBreast cancer treatmentCancer patient cohortsBreast cancer therapyQuality of lifeDifferent treatment groupsAI therapyChart reviewTreatment initiationMass index
2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDexamethasoneDiphenhydramineDrug Administration ScheduleDrug HypersensitivityFamotidineFemaleHumansInfusions, IntravenousMiddle AgedNeoplasm StagingPaclitaxelPremedicationProspective StudiesRetrospective StudiesConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyRescue medication useBreast cancer patientsHypersensitivity reactionsPaclitaxel dosesRescue medicationMedication useSecond doseCancer patientsBreast cancerLife-threatening complicationsMajority of patientsDoses of paclitaxelProspective pilot trialUse of paclitaxelBreast cancer treatmentPrimary endpointInfusion reactionsPremedication regimenSubsequent dosesUnwanted side effectsResultsIn totalPilot trialStudy population